These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11566038)

  • 21. The economic consequences of NSAID-induced gastrointestinal damage.
    de Pouvourville G; Tasch RF
    Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C; Stafford RS; Alexander GC
    Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia.
    Kearney DJ; Liu CF; Crump C; Brousal A
    Am J Gastroenterol; 2003 Sep; 98(9):1952-62. PubMed ID: 14499771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention.
    Scheiman JM
    Rev Gastroenterol Disord; 2005; 5 Suppl 2():39-49. PubMed ID: 16369226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
    Harris CL; Raisch DW; Abhyankar U; Marfatia S; Campbell HM; Sather MR
    Ann Pharmacother; 2006 Nov; 40(11):1924-31. PubMed ID: 17047140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.
    Morant SV; Shield MJ; Davey PG; MacDonald TM
    Pharmacoepidemiol Drug Saf; 2002; 11(5):393-400. PubMed ID: 12271881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey.
    Chey WD; Eswaren S; Howden CW; Inadomi JM; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2006 Mar; 23(5):655-68. PubMed ID: 16480405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs.
    Ofman JJ; Maclean CH; Straus WL; Morton SC; Berger ML; Roth EA; Shekelle PG
    Arthritis Rheum; 2003 Aug; 49(4):508-18. PubMed ID: 12910557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disadvantageous effects of nonsteroidal anti-inflammatory drugs on the alimentary tract.
    Cichoz-Lach H; Celiński K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):403-8. PubMed ID: 12898870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
    Inotai A; Mészáros A
    Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-steroidal antiinflammatory drugs. A review.
    Winzeler S; Rosenstein BD
    AAOHN J; 1998 May; 46(5):253-9; quiz 260-1. PubMed ID: 9652239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NSAID-related upper gastrointestinal bleeding: are risk factors considered during prophylaxis?
    Dincer D; Duman A; Dikici H; Arici C; Suleymanlar I; Isitan F
    Int J Clin Pract; 2006 May; 60(5):546-8. PubMed ID: 16700851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
    Rahme E; Pettitt D; LeLorier J
    Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs.
    Vonkeman HE; Klok RM; Postma MJ; Brouwers JR; van de Laar MA
    Drugs Aging; 2007; 24(8):681-90. PubMed ID: 17702536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.